Suppr超能文献

使用机器学习K均值聚类分析对囊性纤维化患者急性肺部加重期的症状进行表型分析。

Symptom phenotyping in people with cystic fibrosis during acute pulmonary exacerbations using machine-learning K-means clustering analysis.

作者信息

Gill Eliana R, Dill Christopher, Goss Christopher H, Sagel Scott D, Wright Michelle L, Horner Sharon D, Zuñiga Julie A

机构信息

Division of Biobehavioral Nursing and Health Informatics, Department of Nursing, University of Washington, Seattle, WA, United States.

University of Houston, Houston Texas, United States.

出版信息

J Cyst Fibros. 2024 Nov;23(6):1106-1111. doi: 10.1016/j.jcf.2024.05.014. Epub 2024 Jun 8.

Abstract

INTRODUCTION

People with cystic fibrosis (PwCF) experience frequent symptoms associated with chronic lung disease. A complication of CF is a pulmonary exacerbation (PEx), which is often preceded by an increase in symptoms and a decline in lung function. A symptom cluster is when two or more symptoms co-occur and are related; symptom clusters have contributed meaningful knowledge in other diseases. The purpose of this study is to discover symptom clustering patterns in PwCF during a PEx to illuminate symptom phenotypes and assess differences in recovery from PExs.

METHODS

This study was a secondary, longitudinal analysis (N = 72). Participants at least 10 years of age and being treated with intravenous antibiotics for a CF PEx were enrolled in the United States. Symptoms were collected on treatment days 1-21 using the CF Respiratory Symptom Diary (CFRSD)-Chronic Respiratory Symptom Score (CRISS). K-means clustering was computed on day 1 symptom data to detect clustering patterns. Linear regression and multi-level growth models were performed.

RESULTS

Symptoms significantly clustered based on severity: low symptom (LS)-phenotype (n = 42), high symptom (HS)-phenotype (n = 30). HS-phenotype had worse symptoms and CRISS scores (p< 0.01) than LS-phenotype. HS-phenotype was associated with spending 5 more nights in the hospital annually (p< 0.01) than LS-phenotype. HS-phenotype had worse symptoms over 21 days than LS-phenotype (p< 0.0001).

CONCLUSION

Symptoms significantly cluster on day 1 of a CF-PEx. PwCF with HS-phenotype spend more nights in the hospital and are less likely to experience the same resolution in symptoms by the end of PEx treatment than LS-phenotype.

摘要

引言

囊性纤维化患者(PwCF)经常出现与慢性肺病相关的症状。囊性纤维化的一种并发症是肺部加重(PEx),通常在症状加重和肺功能下降之前出现。症状群是指两种或更多症状同时出现且相互关联的情况;症状群在其他疾病中已提供了有意义的知识。本研究的目的是发现PwCF在肺部加重期间的症状聚类模式,以阐明症状表型并评估肺部加重恢复过程中的差异。

方法

本研究是一项二次纵向分析(N = 72)。在美国,纳入了年龄至少10岁且因囊性纤维化肺部加重接受静脉抗生素治疗的参与者。在治疗第1 - 21天使用囊性纤维化呼吸症状日记(CFRSD)-慢性呼吸症状评分(CRISS)收集症状。对第1天的症状数据进行K均值聚类以检测聚类模式。进行了线性回归和多级增长模型分析。

结果

症状根据严重程度显著聚类:低症状(LS)表型(n = 42),高症状(HS)表型(n = 30)。HS表型的症状和CRISS评分比LS表型更差(p < 0.01)。HS表型每年比LS表型多在医院住5晚(p < 0.01)。在21天内,HS表型的症状比LS表型更差(p < 0.0001)。

结论

在囊性纤维化肺部加重的第1天症状显著聚类。与LS表型相比,HS表型的PwCF在医院住的时间更长,并且在肺部加重治疗结束时症状不太可能得到相同程度的缓解。

相似文献

4
Correspondence between symptoms and preference-based health status measures in the STOP study.
J Cyst Fibros. 2019 Mar;18(2):251-264. doi: 10.1016/j.jcf.2018.08.001. Epub 2018 Aug 29.
8
Clinical features associated with pulmonary exacerbation diagnosis in infants and young children with cystic fibrosis.
Pediatr Pulmonol. 2024 Apr;59(4):874-879. doi: 10.1002/ppul.26838. Epub 2023 Dec 22.
9
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment.
J Cyst Fibros. 2021 Jan;20(1):36-38. doi: 10.1016/j.jcf.2020.08.006. Epub 2020 Aug 13.

引用本文的文献

1
Symptom factors and their clinical correlates among adults with cystic fibrosis.
J Cyst Fibros. 2025 Jul 8. doi: 10.1016/j.jcf.2025.07.001.
2
ERS Congress 2024: highlights from the Thoracic Surgery and Lung Transplantation Assembly.
ERJ Open Res. 2025 Jan 27;11(1). doi: 10.1183/23120541.01046-2024. eCollection 2025 Jan.

本文引用的文献

1
Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis.
Ann Am Thorac Soc. 2022 Nov;19(11):1818-1826. doi: 10.1513/AnnalsATS.202111-1266OC.
2
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response.
J Cyst Fibros. 2022 Jul;21(4):588-593. doi: 10.1016/j.jcf.2021.12.003. Epub 2021 Dec 18.
3
Health care costs related to home spirometry in the eICE randomized trial.
J Cyst Fibros. 2022 Jan;21(1):61-69. doi: 10.1016/j.jcf.2021.02.014. Epub 2021 Mar 12.
4
CFTR modulators: transformative therapies for cystic fibrosis.
J Manag Care Spec Pharm. 2021 Feb;27(2):281-284. doi: 10.18553/jmcp.2021.27.2.281.
5
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment.
J Cyst Fibros. 2021 Jan;20(1):36-38. doi: 10.1016/j.jcf.2020.08.006. Epub 2020 Aug 13.
6
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
9
Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
Ann Am Thorac Soc. 2015 May;12(5):708-17. doi: 10.1513/AnnalsATS.201410-493OC.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验